Getting a Read on the EU’s Biosimilar Uptake Across Therapeutic Areas

Posted by Christina Corridon on May 31, 2018 8:00:00 AM

Laura Nielsen co-authored this blog post with Christina Corridon. 

Since the first EU biosimilar approval for Sandoz’s Omnitrope 12 years ago, the European biosimilar market has been difficult to predict. The dynamic policy and regulatory environment, differing levels of payer control, and variability in go-to-market approaches and manufacturing necessitate a bit of guesswork when it comes to predicting how a given biosimilar will perform. 


>
Read More

DTC Biomarker Testing: Please Read the Fine Print

Posted by David Kriesman on May 24, 2018 11:17:42 AM

Pavankumar Anne, Sankalp Sethi and Matt Furlow co-authored this post with David Kriesman.

In oncology, we’re accustomed to “firsts” in the headlines—new discoveries, novel treatments and scientific breakthroughs offering hope to patients. Most newsworthy updates relate to emerging therapies, but on March 6, we saw a first in oncology diagnostic testing that has started making waves.


>
Read More

New ZS Research Answers Three Key Questions About the Oncology Customer Experience in the EU5

Posted by Richard Secker-Johnson on Apr 19, 2018 8:00:00 AM

Malik Kaman co-wrote this blog post with Richard Secker-Johnson. 

For several years now, ZS has been running a customer experience report with oncologists in the U.S., and each year our clients have asked us to explore the impact and drivers of a positive customer experience in Europe, as well. In an online survey, which we fielded to 333 oncologists and hematologists across the EU5 (France, Germany, Italy, Spain and the U.K.), we asked physicians to rate their experiences with the top 18 oncology drug manufacturers. Our goal was to answer three questions facing all oncology manufacturers today. The results offer key insights into how companies can differentiate in this increasingly competitive landscape.


>
Read More

What Are the Next Moves When Checkpoint Inhibitors Fail?

Posted by Vikas Verma on Mar 16, 2018 8:00:00 AM

Marie Yurkovich and Malik Kaman co-authored this blog post with Vikas Verma.

Antibodies that target immune checkpoints, like those against programmed cell death-1 (PD-1) or its ligand (PD-L1), have rapidly changed the oncology treatment landscape for multiple tumor types including melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Opdivo and Keytruda, the flagbearers for anti-PD-1 therapy, have collective sales of more than $8 billion alongside a presence in more than six oncology indications.


>
Read More

AI Is Driving Change in Oncology Practice and Commercialization. Are You Part of the Wave?

Posted by Shankar Viswanathan on Feb 15, 2018 9:15:07 AM

Arup Das co-wrote this blog post with Shankar Viswanathan.

Looking back at 2017, artificial intelligence and machine learning made impressive progress when it comes to improving cancer diagnosis and treatment. Using deep learning, computers are scouring images to detect signs of breast cancer in mammograms earlier than humans are currently capable of. Using AI “random forests,” a learning algorithm, investigators are more accurately predicting which drug combination will work better in BRAF mutant melanoma. The AI-facilitated discovery of Berg Health’s BPM 31510, a pancreatic cancer drug, has entered human development clinical trials. AI is not only powering oncology drug discovery, faster detection and personalized treatment but also helping to improve oncology commercialization effectiveness and agility through analytics. 


>
Read More